Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares (KNSA) Dividend History

Kiniksa Pharmaceuticals International, plc (KNSA) is a biotechnology company focused on developing and commercializing therapies for immune-mediated and inflammatory diseases. Founded in 2015 and headquartered in Bermuda, the company leverages its platform to create innovative treatments aimed at addressing unmet medical needs, particularly in the fields of dermatology, rheumatology, and other immunology-related conditions.

23 Old Bond Street, Floor 3, London, X0, WIS 4PZ
Phone: (781) 431-9100
Website: https://www.kiniksa.com

Dividend History

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares currently does not pay dividends

Company News

Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis

Kiniksa Pharmaceuticals announces plans for a Phase 2/3 clinical trial of its drug KPL-387 in recurrent pericarditis, with the trial expected to initiate in mid-2025 and Phase 2 data expected in the second half of 2026.

GlobeNewswire Inc.
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

Kiniksa Pharmaceuticals announced that country star Carly Pearce has joined their Life DisRPted campaign to raise awareness for recurrent pericarditis. The company also reported strong Q1 2025 financial results for their ARCALYST product, with net product revenue of $137.8 million and increased 2025 revenue guidance.

GlobeNewswire Inc.
3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now

The article highlights three healthcare stocks that are considered good investments right now: AbbVie, Vertex Pharmaceuticals, and Kiniksa Pharmaceuticals. It discusses the growth prospects and financial metrics of these companies.

The Motley Fool

Featured Companies: ABBV VRTX
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Kiniksa Pharmaceuticals, a biopharmaceutical company, announced that it will host a conference call on February 25, 2025, to report its fourth quarter and full year 2024 financial results and recent portfolio execution.

GlobeNewswire Inc.
Evolving Landscape of Cardiology Segment: Key Market Insights of Latest Published Rare Cardiovascular Diseases Report — Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy | DelveInsight

The article discusses the evolving landscape of rare cardiovascular diseases, including Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy. It highlights the challenges in diagnosis and treatment, as well as the growing market size and pipeline of new therapies for these conditions.

GlobeNewswire Inc.

Featured Companies: ABBV CPIX GOSS INSM JNJ LQDA MRK TENX THC UTHR

Dividend data last updated 06/06/2025 19:54:07 UTC